This report covers a new study in Southern Norway that tests a wearable patch ECG for post stroke atrial fibrillation as part of secondary prevention after ischemic stroke; results are not yet available.
The Southern Norway Post Stroke Atrial Fibrillation Study is led by Sorlandet Hospital HF and seeks to evaluate a patch based rhythm monitoring device against standard care in adults with atrial fibrillation who have experienced an ischemic stroke. The investigational device is a wearable patch ECG that is intended to monitor heart rhythm continuously and detect atrial fibrillation events over time. Participants will be assigned to receive either the patch based device in addition to usual care or standard care alone. The record lists two arms and a sponsor, but it does not provide detailed information about randomization, endpoints, duration, or sample size. Recruitment is currently ongoing as of February 13 2026, and the trial is registered on ClinicalTrials.gov under the identifier provided in the source text. The sponsor is Sorlandet Hospital HF, and the site is located in Southern Norway.
What is changing in this study
The entry notes a new focus on rhythm monitoring for patients with atrial fibrillation after stroke. It contrasts a wearable patch ECG device against standard care to assess how continuous rhythm data could inform secondary prevention strategies. The update is relevant for clinicians involved in stroke care and for regulators evaluating the potential use of wearables as medical devices in this indication. Given the file is a recruitment record, it signals a growing interest in non invasive monitoring tools to support decision making in post stroke care.
How is the study designed
Documentation shows two groups, patch device and standard care, with Sorlandet Hospital HF listed as sponsor. The record does not publish protocol level details such as randomization scheme, endpoints, sample size, or study duration. The absence of these specifics means practitioners should await the full protocol for regulatory interpretation while noting that the patch device is classified as an investigational device in this trial. The status remains recruiting as of the stated date, indicating ongoing participant enrollment or planning activities. This setup supports a regulatory assessment of feasibility and safety before any conclusions on performance can be drawn.
What is the device used and how is it applied
The investigational device is described as a wearable patch ECG. It is intended to provide continuous rhythm monitoring and detect atrial fibrillation events during follow up after stroke. The control arm uses standard care without patch monitoring. No efficacy outcomes or safety results are reported in the source text. The device is referenced in the context of a comparative trial rather than a marketed medical device, and the sponsor has not released additional technical specifications in this record.
Who is eligible and where is it conducted
Eligible participants are adults diagnosed with atrial fibrillation in the context of secondary stroke prevention. The trial site is Sorlandet Hospital HF in Southern Norway, and recruitment is ongoing. The study is listed on ClinicalTrials.gov with the identifier NCT07407790. Because the record does not include a full protocol, details on inclusion and exclusion criteria or geographic reach beyond the listed site are not disclosed here. Regulators will want the complete protocol to verify eligibility standards and risk management plans.
FAQ
- 1. What is the main aim of the study?
To evaluate a wearable patch ECG for rhythm monitoring in adults with atrial fibrillation after an ischemic stroke as part of secondary prevention, in comparison with standard care. - 2. Who sponsors the study?
Sorlandet Hospital HF is listed as the sponsor. - 3. Where is the study being conducted?
At Sorlandet Hospital HF in Southern Norway, with recruitment listed as ongoing as of February 13 2026.
In summary, this study represents a regulatory aware step toward validating a wearable patch ECG for long term rhythm monitoring in post stroke atrial fibrillation. Until protocol specifics and outcome data are disclosed, stakeholders should monitor the ClinicalTrials.gov entry for updates and await detailed regulatory submissions that address intended use, device safety, and performance claims.
Disclaimer: This summary is provided for professional informational purposes and does not constitute legal advice. It reflects the information available from the source text and cited records.
https://clinicaltrials.gov/study/NCT07407790?term=medical+device